Artemis Therapeutics Inc.
ATMS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1,090.46 | 1.95 | 0.00 | 0.02 |
| FCF Yield | -0.00% | -0.29% | -0.09% | -75.00% |
| EV / EBITDA | -49,283.63 | -162.51 | -7.28 | -1.46 |
| Quality | ||||
| ROIC | 213.72% | 55.33% | 49.42% | 86.54% |
| Gross Margin | 82.64% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.29 | 0.44 | 0.01 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | -469.86% | -7,200.00% | 99.07% | 79.15% |
| Safety | ||||
| Net Debt / EBITDA | -0.22 | -1.27 | -0.65 | -0.60 |
| Interest Coverage | 0.00 | -11.85 | -23.86 | -28.00 |
| Efficiency | ||||
| Inventory Turnover | 1.15 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,493.73 | 0.00 | 0.00 | 0.00 |